Villere ST Denis J & Co. LLC reduced its stake in shares of Alpha Cognition Inc. (NASDAQ:ACOG – Free Report) by 11.1% during the second quarter, Holdings Channel.com reports. The firm owned 63,838 shares of the company’s stock after selling 7,940 shares during the period. Villere ST Denis J & Co. LLC’s holdings in Alpha Cognition were worth $596,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, Salem Investment Counselors Inc. bought a new stake in shares of Alpha Cognition during the first quarter valued at about $230,000.
Alpha Cognition Trading Down 7.3%
Shares of Alpha Cognition stock opened at $7.02 on Friday. The company’s 50-day moving average price is $8.36 and its two-hundred day moving average price is $8.05. Alpha Cognition Inc. has a 52 week low of $3.75 and a 52 week high of $11.54. The stock has a market cap of $146.72 million, a PE ratio of -4.39 and a beta of 2.63.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Alpha Cognition currently has a consensus rating of “Buy” and a consensus price target of $20.00.
View Our Latest Research Report on Alpha Cognition
Insider Activity
In related news, Director Robert James Wills acquired 15,000 shares of the business’s stock in a transaction on Monday, August 18th. The shares were purchased at an average price of $8.49 per share, for a total transaction of $127,350.00. Following the acquisition, the director owned 15,000 shares in the company, valued at approximately $127,350. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip Joseph Mertz sold 27,778 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $9.00, for a total value of $250,002.00. Following the sale, the director owned 22,462 shares in the company, valued at approximately $202,158. The trade was a 55.29% decrease in their position. The disclosure for this sale can be found here. 14.00% of the stock is currently owned by insiders.
About Alpha Cognition
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
- Five stocks we like better than Alpha Cognition
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- How to trade penny stocks: A step-by-step guide
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- 3 Ways To Invest In Coffee, Other Than Drinking It
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Want to see what other hedge funds are holding ACOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Cognition Inc. (NASDAQ:ACOG – Free Report).
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.